TI
RNAC icon

Trexquant Investment’s Cartesian Therapeutics RNAC Stock Holding History

Trexquant Investment’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-641
Closed -$351K – 1229
2017
Q3 		$351K Buy
641
+80
+14% +$42.5K 0.09% 405
2017
Q2 		$334K Buy
+561
New +$248K 0.09% 409

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's RNAC Position: Q4 2017 in Review

Trexquant Investment sold out of Cartesian Therapeutics (RNAC) in Q4 2017, closing a stake of 641 shares — an estimated $351K sold.

Trexquant Investment first reported a position in RNAC in Q2 2017 and held it in 2 quarters. The position peaked at $351K in Q3 2017. 63 funds tracked by Wall St. Rank hold RNAC as of Q4 2017.

  • Trexquant Investment reported no remaining Cartesian Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Trexquant Investment sold 641 Cartesian Therapeutics shares in Q4 2017, an estimated $351K.
  • Trexquant Investment first reported a position in Cartesian Therapeutics in Q2 2017 and held it in 2 quarters.
  • Trexquant Investment's Cartesian Therapeutics position peaked at $351K in Q3 2017.
  • 63 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2017.

Based on Trexquant Investment's 13F filing for Q4 2017, filed 9 Feb 2018.